Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2015 | Can we afford to have CLL patients on a therapy for the rest of their lives?

John Gribben and Stephan Stilgenbauer • 4 Dec 2015
ASH 2015
Chronic Lymphocytic Leukemia

At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the challenges of long-term therapy in chronic lymphocytic leukemia (CLL) patients.

More from John Gribben

Investigating the treatment preferences of physicians in R/R follicular lymphoma 2:42
Investigating the treatment preferences of physicians in R/R follicular lymphoma
John Gribben • 9 Dec 2023
Axi-cel in R/R FL: an updated comparison of ZUMA-5 and the SCHOLAR-5 external control cohort 1:20
Axi-cel in R/R FL: an updated comparison of ZUMA-5 and the SCHOLAR-5 external control cohort
John Gribben • 9 Dec 2023
The future of CLL therapy 1:04
The future of CLL therapy
John Gribben • 9 Dec 2023
Novel therapies in NHL: antibody-drug conjugates
Andrew Davies et al. • 17 Oct 2023

More from Stephan Stilgenbauer

Obinutuzumab, ibrutinib, and venetoclax in high-risk CLL: the CLL2-GIVe and CLL13 trials 2:00
Obinutuzumab, ibrutinib, and venetoclax in high-risk CLL: the CLL2-GIVe and CLL13 trials
Stephan Stilgenbauer • 11 Dec 2023
Acquired mutations associated with resistance to BTKi in patients with CLL 2:52
Acquired mutations associated with resistance to BTKi in patients with CLL
Stephan Stilgenbauer • 11 Dec 2023
Genetic markers in patients with early-stage CLL treated with ibrutinib: findings from CLL12 2:51
Genetic markers in patients with early-stage CLL treated with ibrutinib: findings from CLL12
Stephan Stilgenbauer • 11 Dec 2023
Pre-clinical study on the dual BCL2/BCL-XL inhibitor AZD0466 for the treatment of CLL 2:11
Pre-clinical study on the dual BCL2/BCL-XL inhibitor AZD0466 for the treatment of CLL
Stephan Stilgenbauer • 11 Dec 2023

Related Videos

Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study 3:24
Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study
Nirav Niranjan Shah • 24 Sep 2025
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines 1:56
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines
Nirav Niranjan Shah • 24 Sep 2025
BTK degraders in CLL: how may these agents shape the field? 1:30
BTK degraders in CLL: how may these agents shape the field?
Nirav Niranjan Shah • 24 Sep 2025
The importance of understanding the mechanisms underlying Richter’s transformation 1:15
The importance of understanding the mechanisms underlying Richter’s transformation
Gianluca Gaidano • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals